Epigenetics Market Is Expected to Reach $1,321 Million, Globally, by 2023


quote Epigenetics has provided hope for advanced cancer treatment, and is expected to be the one of the most effective treatment options for diseases in future, especially cancer. The rise in awareness about epigenetic factors and their role in developmental & disease biology are anticipated to create lucrative opportunities in the forecast period. quote

Sriram Radhakrishnan
Team Lead, Healthcare at Allied Market Research.

Get 20% Free Customization In This Report
Follow us on Social Media:       

According to a new report published by Allied Market Research, titled, "Epigenetics Market by Product, Application, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global epigenetics market was valued at $555 million in 2016, and is projected to reach $1,321 million by 2023, growing at a CAGR of 13.1% from 2017 to 2023. The DNA-modifying enzymes segment witnessed the highest rate, generating maximum revenue in the market in 2016.

Access Full Summary at: https://www.alliedmarketresearch.com/epigenetics-market

Epigenetics is an area of developmental biology that involves the study of cellular and physiological trait variations initiated by external or ecological aspects. This external stimulus swipe genes on and off and affect the ability of cells to read genes. Epigenetics changes the organisms phenotype rather than the genotype, wherein the underlying DNA or RNA sequence remains unchanged. For instance, DNA methylation and histone modification are epigenetic processes wherein the alteration in gene expression is observed without the change in the DNA sequence. The increase in usage and application of epigenetics to formulate drugs to treat different oncology and non-oncology related diseases is expected to boost the market growth.

The major factors that drive the global epigenetics market are rise in cancer prevalence; improved funding & aids for R&D activities, surge in partnership between academic, pharmaceutical, and biotechnology companies, and increased application of epigenetics in non-oncology diseases. However, high cost of instruments and lack of trained professionals are factors that impede the growth of this market. Furthermore, untapped potential of emerging markets provides lucrative opportunities to the market players.

The kits & assays product segment occupies the highest share in epigenetics product market, owing to their sheer usage and need throughout the protocol and other pre-requisite steps of DNA analysis. The next-generation sequencers segment witnessed the highest growth rate, and accounted for over half of the total share in 2016, and is anticipated to dominate the market. This is attributed to most of the epigenetic investigations that utilize this technology to achieve their desired objective.

At present, oncology dominates the application segment and is expected to grow at a CAGR of 12.8% during the forecast period. Drugs based on epigenetics are reported to be incredibly effective and aid reverse abnormal gene expression. Abnormal gene expression causes an array of different diseases, especially cancer and respiratory diseases.

Key Findings of the Epigenetics Market:

  • The kit & assays product segment is anticipated to grow at the highest CAGR from 2017 to 2023.
  • The oncology application segment is expected to witness the highest growth rate during the forecast period.
  • The academic & government research institutes segment generated the highest revenue in 2016, and is expected to continue its dominance in the near future.
  • North America dominated the global epigenetics market, and is projected to grow at a CAGR of 12.3%.
  • Asia-Pacific is expected to witness the highest growth rate during the forecast period.

The major companies profiled in the report include Abcam plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com


For Media Inquiries, Please Contact

Shaun Godinho
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at


First time buyer?
Check offers and discount on this report
To get this report

Click Here

quote Epigenetics Market by Product [Enzymes (DNA Ligases, DNA Polymerases, Other DNA-modifying Enzymes), Kits & Assays (Bisulfite Conversion Kits, Chip-Seq Kits, Deep Sequencing Kits, Methyltransferase Assays, Histone Assays, Immunoprecipitation Kits), Instruments (Mass Spectrometers, Next-generation Sequencers, qPCRs, and Sonicators), and Reagents (Antibodies, Buffers, Histones, Magnetic Beads, Primers, and Other Epigenetics Reagents)], Application (Oncology and Non-oncology Diseases, Developmental Biology, Drug Discovery, and Others), and End User [Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs)] - Global Opportunity Analysis and Industry Forecast, 2017-2023 quote

View Report

Why Allied Market Research?


Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction


On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers


Featured Readings


Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

Get Industry Data Alerts

Buy Full Version
"Epigenetics Market"
Purchase Enquiry